期刊文献+

紫杉醇亚微球制备及治疗小鼠乳腺癌的实验研究 被引量:3

Experimental study on paclitaxol-PCL nanoparticles in mouse breast cancer
暂未订购
导出
摘要 目的观察紫杉醇亚微球对小鼠乳腺癌的治疗效果。方法以可生物降解材料聚己内酯(poly-caprolacton,PCL)为原料,采用溶剂替代法制备载紫杉醇亚微球。并对亚微球的粒径、形态、紫杉醇含量、体外释放等进行了测定。将TA2系实验小鼠随机分为空白对照组、紫素阳性对照组、紫杉醇亚微球低剂量组、紫杉醇亚微球中剂量组及紫杉醇亚微球高剂量组。实验时分别将生理盐水、紫素、紫杉醇亚微球注射到小鼠乳腺癌部位,通过测量治疗前后肿瘤大小,观察紫杉醇亚微球治疗实验小鼠乳腺癌的效果。结果制备的紫杉醇亚微球的平均粒径约为566nm,包埋率为93.25%,亚微球中紫杉醇含量约19.0536%。可在体外维持恒定释放约4周。药物注射2周观察抑瘤率:紫杉醇亚微球中剂量组为70.21%,紫杉醇亚微球高剂量组为84.16%,与紫素阳性对照组(48.96%)比较差异有显著统计学意义(P<0.001)。紫杉醇亚微球低剂量组为45.47%,与紫素阳性对照组相比,两者差异亦有显著统计学意义(P<0.001)。结论紫杉醇亚微球(中剂量组和高剂量组)对小鼠乳腺癌的抑瘤率高于紫素。 Objective To study the therapeutic efficacy of paclitaxel-PCL nanoparticles in mouse breast cancer. Methods A biodegradable poly-caprolacton (PCL) was adopted as drug delivery material. Paclitaxel drug delivery nanoparticles (NP) were prepared by a multi-emulsification technique. The nanoparticles were characterized for size, drug loading capacity, and in vitro release. The experimental mice were randomly divided into vacant control group, paclitaxel positive control group, Paclitaxel-NP low-dose group, Paclitaxel-NP meta-dose group and Paclitaxel-NP high dose group. Paclitaxel or Paclitaxel-NP was injected into mouse breast cancer,then the tumor size was measured. Results The average size of Paclitaxel-NP was around 300 nm. The encapsulation efficiency of Paclitaxel was above 96 %. Loading amount of Paclitaxel in the nanoparticles was about 4 %. In vitro ,nanoparticles maintained sustaining release of Paclitaxel for 2 weeks. After 2 week ,the inhibition ratio of tumor growth in Paclitaxel-NP meta-dose group was 70.21% ,in Paclitaxel-NP high dose group was 84.16 % ,in Paclitaxel positive control group was 48.96 %. The differences of both groups compared with control were significant (P 〈 0.001 ) ;in Paclitaxel-NP low-dose group was 45.4 % ,showing was significant difference compared with control (P 〈 0.001 ). Conclusion The inhibition ratio of tumor growth in Paclitaxel-NP (meta-dose group and high dose group) is higher than that in paclitaxel group.
出处 《生物医学工程与临床》 CAS 2007年第3期174-178,F0003,共6页 Biomedical Engineering and Clinical Medicine
基金 国家自然科学基金(50473059) 博士点基金(20030023004) 天津市自然科学基金(05YFJMJC10100 043803011)
关键词 紫杉醇 PCL亚微球 小鼠 乳腺癌 paclitaxel poly- caprolacton (PCL) nanoparticles mouse breast cancer
  • 相关文献

参考文献13

  • 1Ishihara M,Obara K,Nakamura S,et al.Chitosan hydrogel as a drug delivery carrier to control angiogenesis[J].J Artif Organs,2006,9(1):8-16.
  • 2Xie J,Wang CH.Self-assembled biodegradable nanoparticles developed by direct dialysis for the delivery of paclitaxel[J].Pharm Res,2005,22(1 2):2079-2090.
  • 3Dong Y,Feng SS.Nanoparticles of poly(D,L-lactide)/methoxy poly(ethylene glycol)-poly(D,L-lactide)blends for controlled release of paclitaxel[J].J Biomed Mater Res A,2006,78(1):12-19.
  • 4葛海雄,蒋锡群,杨时成,杨昌正.可生物降解高分子纳米微粒的制备及表征[J].高分子材料科学与工程,2001,17(1):64-67. 被引量:5
  • 5孙慧,郝希山,战忠利,杨海贤,张爱莲,马杰,高进.TA2系小鼠乳腺癌肺转移(BCML-TA299)模型的建立及生物学特性的实验研究[J].中国肿瘤临床,2003,30(12):886-890. 被引量:14
  • 6Thurmond KB,Remsen EE,Kowalewski T,et al.Packaging of DNA by shell crosslinked nanoparticles[J].Nucleic Acids Res,1999,27(14):2966-2971.
  • 7Trnong-Le VL,August JT,Leong KW.Controlled gene delivery by DNA-gelatin nanopheres[J].Hum Gene Ther,1998,9(12):1709-1717.
  • 8吕大鹏,李力军,等.纳米技术与肿瘤防治[J].中国实用外科杂志,2002,22(2):126-128. 被引量:14
  • 9Dong Y,Feng SS.Methoxy poly(ethylene glyc01)-poly(lactide)(MPEG-PLA)nanoparticles for controHed delivery of anticancer drugs[J].Biomaterials,2004,25(14):2843-2849.
  • 10Sinha VR,Bansal K,Kaushik R,et al.Poly-epsilon-caprolactone miempheres and nanospheres:an overview[J].Int J Phann,2004,278(1):1-23.

二级参考文献45

  • 1孙慧,候子正,战忠利,毛慧生,王垣,宁连胜,韩宝国,齐淑玲,苏明秀,高进.近交系TA_2小鼠的恶性淋巴瘤(L-TA_2)模型的建立和某些生物学特性的观察[J].中国肿瘤临床,1993,20(10):783-787. 被引量:7
  • 2孙慧,战忠利,黄建英,毛慧生.人卵巢癌裸鼠移植瘤模型的建立及其生物学特性的实验应用研究[J].中国肿瘤临床,1994,21(10):786-791. 被引量:12
  • 3施新猷主编.医用实验动物学[M].西安:陕西科学出版社,1988.453~470.
  • 4鄂征主编.组织培养和分子生物技术[M].北京:北京出版社,1995.164~166.
  • 5Zhang X,J Macromol Sci Pure Appl Chem.A,1993年,30卷,933页
  • 6Kwon HY, Lee JY, Choi SW, et al. Preparation of PLGA nanoparticles containing estrogen by emulsification-diffusion method[J]. Colloids and Surfaces A:Physicochemical and Engineering Aspects,2001,182 (1-3) :123.
  • 7Hideki Murakami, Masao Kobayashi.Hirofumi Takeuchi, et al.Further application of a modified spontaneous emulsification solvent diffusion method to various types of PLGA and PLA polymers for preparation of nanoarticles[J].Power Technology,2000,107(1-2):137.
  • 8Hideki Murakami, Masao Kobayashi, Hirofumi Takeuchi, et al.Preparation of poly ( DL-lactide-co-glycolide ) nanoparticles by modified spontaneous emulsification solvent diffusion method [ J ].Int J Pharm,1999,187(2) :143.
  • 9Gref R, Luck M, Quellec P, et al.stealth corona-core nanoparticles surface modified by polyethylene glycol( PEG ) : influences of the corona ( PEG chain length and surface density) of the core composition on phagocyiic uptake and plasma protein adsorption[ J]. Colloids Surfaces B-Biointerfaces ,2000,18 (34) :301.
  • 10Kim SY, Ha JC, Lee YM. Poly ( ethylene oxide ) -poly ( propylene oxide) -poly( ethylene oxide )/poly ( epsilon-caprolactone ) ( PCL )amphiphilic block copolymeric nanoparticles- Ⅱ. Thermo-responsive drug release behaviors [ J ]. J Controlled Release, 2000,65(3) :345.

共引文献33

同被引文献45

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部